Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Viridian Therapeutics Inc
(NQ:
VRDN
)
17.51
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
17.51
Bid (Size)
7.010 (2)
Ask (Size)
19.25 (1)
Prev. Close
17.51
Today's Range
17.51 - 17.51
52wk Range
10.93 - 30.30
Shares Outstanding
9,587,155
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Unveiling 4 Analyst Insights On Viridian Therapeutics
March 20, 2024
Via
Benzinga
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
March 19, 2024
Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them.
Via
InvestorPlace
Performance
YTD
-21.66%
-21.66%
1 Month
-9.13%
-9.13%
3 Month
-22.18%
-22.18%
6 Month
+13.92%
+13.92%
1 Year
-30.07%
-30.07%
More News
Read More
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Navigating 6 Analyst Ratings For Viridian Therapeutics
February 28, 2024
Via
Benzinga
Analyst Ratings for Viridian Therapeutics
December 04, 2023
Via
Benzinga
Where Viridian Therapeutics Stands With Analysts
November 14, 2023
Via
Benzinga
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
February 16, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
January 18, 2024
Via
Benzinga
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
December 18, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
December 18, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
November 08, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
November 03, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
October 30, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
October 26, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
October 03, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.